What heparin (unfractionated heparin or low‑molecular‑weight heparin) is preferred for patients with chronic kidney disease and how should the dose be adjusted based on estimated glomerular filtration rate?

Heparin Selection in Chronic Kidney Disease

In patients with CKD, unfractionated heparin (UFH) is the preferred anticoagulant for therapeutic anticoagulation, particularly when eGFR is <30 mL/min, because it does not require renal clearance and can be monitored with aPTT. 1

Choice of Heparin by Kidney Function

eGFR ≥50 mL/min

• Either UFH or LMWH can be used at standard doses
• LMWH offers convenience with subcutaneous dosing and no monitoring required
• Standard weight-based dosing applies 2

eGFR 30-50 mL/min

• LMWH requires dose reduction (typically 25-50% reduction)
• Consider anti-Xa monitoring with target 1.0-2.0 IU/mL (once daily) or 0.5-1.0 IU/mL (twice daily) 3
• UFH is safer as it avoids accumulation risk and allows immediate dose adjustment 4, 5

eGFR <30 mL/min (CKD Stage 4-5)

• UFH is strongly preferred 4, 6
• LMWH accumulates significantly due to renal clearance, increasing bleeding risk
• If LMWH must be used, reduce dose by 50% and monitor anti-Xa levels closely 3, 6

Dialysis Patients (ESRD)

• UFH is the anticoagulant of choice 4
• Short half-life allows precise control during and between dialysis sessions
• For hemodialysis: 25-30 units/kg bolus, then 1,500-2,000 units/hour infusion 1

Dosing Adjustments for UFH

UFH dosing does not require adjustment based on kidney function, but monitoring is essential 1:

• Target aPTT: 1.5-2 times normal (or 60-85 seconds in pediatrics)
• Monitoring frequency: Every 4 hours initially, then at appropriate intervals
• Therapeutic regimens (from FDA label):
  • IV continuous infusion: 5,000 unit bolus, then 20,000-40,000 units/24 hours
  • Intermittent IV: 10,000 unit initial dose, then 5,000-10,000 units every 4-6 hours
  • Subcutaneous: 5,000 unit IV bolus, then 10,000-20,000 units SC every 8-12 hours

Critical Monitoring Considerations

All CKD patients on heparin require:

• Baseline and periodic platelet counts (risk of HIT)
• Hematocrit monitoring
• Occult blood in stool testing
• More frequent coagulation monitoring in severe CKD (eGFR <30) 1

Common Pitfalls to Avoid

1. Do not use standard LMWH doses when eGFR <50 mL/min - accumulation leads to bleeding 3, 6
2. Weight-based LMWH dosing may be misleading in obese patients with renal impairment 2
3. Avoid fondaparinux entirely in severe renal impairment (eGFR <30) 6
4. Do not assume LMWH is safer than UFH in CKD - the opposite is true in advanced disease 4, 5

Why UFH is Preferred in Advanced CKD

The evidence consistently supports UFH over LMWH in moderate-to-severe CKD because:

• No renal clearance required - metabolized by reticuloendothelial system 5, 6
• Immediate reversibility with protamine sulfate 1
• Real-time monitoring with aPTT allows precise dose titration 4
• Shorter half-life reduces bleeding risk in this high-risk population 4

While LMWH offers convenience in patients with normal kidney function, this advantage disappears when renal impairment necessitates dose reduction and anti-Xa monitoring 2, 3. The 2001 AHA guideline acknowledges LMWH's predictable dose response but specifically warns that "weight-adjusted dosing could be misleading in patients with renal insufficiency" 2.